Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with or without tifcemalimab as consolidation after chemoradiotherapy for limited-stage small cell lung cancer
2023-507097-41-01Phase 3Authorised
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of toripalimab and tifcemalimab in small cell lung cancer (SCLC) (3 arms), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoints: Overall survival and Blinded independent review committee-assessed progression-free survival. Planned start Feb 2025; status: authorised.
02
Drugs
toripalimabtifcemalimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2023-507097-41-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507097-41-01.